Do you want to read an article? Please log in or register.
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A
Non-Malignant Blood Disorders
Related content
Non-Malignant Blood Disorders
Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor
Blood Rev.
Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E
doi: 10.1016/j.blre.2019.04.001.
RECOMMENDED
Non-Malignant Blood Disorders
2020 Clinical Trials Update: Innovations in Hemophilia Therapy
★ 1
Recommended by
Alexander Meisel, Faculty Member
Am J Hematol.
Croteau SE, Wang M, Wheeler AP
doi: 10.1002/ajh.26018.
Non-Malignant Blood Disorders
Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B
Drugs.
Lyseng-Williamson KA
doi: 10.1007/s40265-016-0679-8.
Non-Malignant Blood Disorders
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
N Engl J Med.
Pasi KJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B, Laffan M, Russell CB, Li M, Pierce GF, Wong WY
doi: 10.1056/NEJMoa1908490.
Non-Malignant Blood Disorders
Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial
Lancet Haematol
van Moort I, Preijers T, Bukkems LH, Hazendonk HCAM, van der Bom JG, Laros-van Gorkom BAP, Beckers EAM, Nieuwenhuizen L, van der Meer FJM, Ypma P, Coppens M, Fijnvandraat K, Schutgens REG, Meijer K, Leebeek FWG, Mathôt RAA, Cnossen MH, OPTI-CLOT study group.
doi: 10.1016/S2352-3026(21)00135-6
SPECIAL REPORT
Multiple Myeloma (MM)
Therapie des rezidivierten/refraktären Multiplen Myeloms
Breast CancerGynecologic Cancer
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers
JAMA Oncol.
Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group
doi: 10.1001/
Non-Malignant Blood Disorders
Bleeding and Response to Hemostatic Therapy in Acquired Hemophilia A (AHA): Results from the GTH-AH 01/2010 Study
Blood.
Holstein K, Liu X, Smith A, Knöbl P, Klamroth R, Geisen U, Eichler H, Miesbach W, Tiede A
doi: 10.1182/blood.2019003639.
Therapy management of metastatic prostate carcinoma in general practice
a ADT: Androgen-Deprivation Therapy
b MRI: Magnetic Resonance Imaging
c CYP17: 17α-hydroxylase/C17, 20-lyase or cytochrome-P450-17